Literature DB >> 17409205

Frequent occult infection with Cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis.

Luciano Potena1, Cecile T J Holweg, Marcy L Vana, Leena Bashyam, Jaya Rajamani, A Louise McCormick, John P Cooke, Hannah A Valantine, Edward S Mocarski.   

Abstract

Despite antiviral prophylaxis, a high percentage (over 90%) of heart transplant patients experience active cytomegalovirus (CMV) infection, diagnosed by detection of viral DNA in peripheral blood polymorphonuclear leukocytes within the first few months posttransplantation. Viral DNA was detected in mononuclear cells prior to detection in granulocytes from CMV-seropositive recipients (R+) receiving a heart from a CMV-seropositive donor (D+). Based on assessment of systemic infection in leukocyte populations, both R+ subgroups (R+/D- and R+/D+) experienced a greater infection burden than the R-/D+ subgroup, which was aggressively treated because of a higher risk of acute CMV disease. Despite widespread systemic infection in all at-risk patient subgroups, CMV DNA was rarely (< 3% of patients) detected in transplanted heart biopsy specimens. The R+ patients more frequently exceeded the 75th percentile of the CMV DNA copy number distribution in leukocytes (110 copies/10(5) polymorphonuclear leukocytes) than the R-/D+ subgroup. Therefore, active systemic CMV infection involving leukocytes is common in heart transplant recipients receiving prophylaxis to reduce acute disease. Infection of the transplanted organ is rare, suggesting that chronic vascular disease attributed to CMV may be driven by the consequences of systemic infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17409205      PMCID: PMC1933112          DOI: 10.1128/JCM.01362-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.

Authors:  R R Razonable; A Rivero; A Rodriguez; J Wilson; J Daniels; G Jenkins; T Larson; W C Hellinger; J R Spivey; C V Paya
Journal:  J Infect Dis       Date:  2001-10-23       Impact factor: 5.226

2.  Association of viral genome with graft loss in children after cardiac transplantation.

Authors:  G S Shirali; J Ni; R E Chinnock; J K Johnston; G L Rosenthal; N E Bowles; J A Towbin
Journal:  N Engl J Med       Date:  2001-05-17       Impact factor: 91.245

Review 3.  Latency and reactivation of human cytomegalovirus.

Authors:  J G P Sissons; M Bain; M R Wills
Journal:  J Infect       Date:  2002-02       Impact factor: 6.072

4.  Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients.

Authors:  G Gerna; D Zipeto; E Percivalle; M Parea; M G Revello; R Maccario; G Peri; G Milanesi
Journal:  J Infect Dis       Date:  1992-12       Impact factor: 5.226

5.  Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone.

Authors:  H A Valantine; H Luikart; R Doyle; J Theodore; S Hunt; P Oyer; R Robbins; G Berry; B Reitz
Journal:  Transplantation       Date:  2001-11-27       Impact factor: 4.939

6.  Diagnosis of human cytomegalovirus infections in the immunocompromised host.

Authors:  G Gerna; M Zavattoni; E Percivalle; D Zella; M Torsellini; M G Revello
Journal:  Clin Diagn Virol       Date:  1996-05

Review 7.  Prevention and treatment of cytomegalovirus disease in heart transplant patients.

Authors:  R H Rubin
Journal:  J Heart Lung Transplant       Date:  2000-08       Impact factor: 10.247

8.  Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.

Authors:  A Beniaminovitz; S Itescu; K Lietz; M Donovan; E M Burke; B D Groff; N Edwards; D M Mancini
Journal:  N Engl J Med       Date:  2000-03-02       Impact factor: 91.245

Review 9.  The role of viruses in cardiac allograft vasculopathy.

Authors:  Hannah A Valantine
Journal:  Am J Transplant       Date:  2004-02       Impact factor: 8.086

10.  Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts.

Authors:  Vincent C Emery; Aycan F Hassan-Walker; Andrew K Burroughs; Paul D Griffiths
Journal:  J Infect Dis       Date:  2002-05-31       Impact factor: 5.226

View more
  12 in total

1.  Cytomegalovirus UL91 is essential for transcription of viral true late (γ2) genes.

Authors:  Shinya Omoto; Edward S Mocarski
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

2.  Cytomegalovirus UL103 controls virion and dense body egress.

Authors:  Jenny Ahlqvist; Edward Mocarski
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

Review 3.  Complications of Cardiac Transplantation.

Authors:  Luciano Potena; Andreas Zuckermann; Francesco Barberini; Arezu Aliabadi-Zuckermann
Journal:  Curr Cardiol Rep       Date:  2018-07-10       Impact factor: 2.931

4.  Simultaneous monitoring of cytomegalovirus-specific antibody and T-cell levels in seropositive heart transplant recipients.

Authors:  Javier Carbone; Nallibe Lanio; Antonio Gallego; Florian Kern; Joaquin Navarro; Patricia Muñoz; Roberto Alonso; Pilar Catalán; Juan Fernández-Yáñez; Jesús Palomo; Manuel Ruiz; Eduardo Fernández-Cruz; Elizabeth Sarmiento
Journal:  J Clin Immunol       Date:  2012-02-29       Impact factor: 8.317

5.  Human cytomegalovirus infection of langerhans-type dendritic cells does not require the presence of the gH/gL/UL128-131A complex and is blocked after nuclear deposition of viral genomes in immature cells.

Authors:  Elvin J Lauron; Dong Yu; Anthony R Fehr; Laura Hertel
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

Review 6.  Acceleration of allograft failure by cytomegalovirus.

Authors:  Daniel N Streblow; Susan L Orloff; Jay A Nelson
Journal:  Curr Opin Immunol       Date:  2007-08-22       Impact factor: 7.486

7.  Comparison of polymerase chain reaction of polymorphonuclear leukocytes and plasma identifies patients who control cytomegalovirus infection after hematopoietic cell transplantation.

Authors:  Marcy L Vana; Danuse Formankova; Steven Cha; Anjali Sharma; Luciano Potena; Janice M Y Brown; Edward S Mocarski
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

Review 8.  Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation.

Authors:  Federico Rea; Luciano Potena; Nizar Yonan; Florian Wagner; Fiorella Calabrese
Journal:  Transplantation       Date:  2016-03       Impact factor: 4.939

9.  Human herpesvirus replication and abnormal CD8+ T cell activation and low CD4+ T cell counts in antiretroviral-suppressed HIV-infected patients.

Authors:  Mark A Jacobson; Dirk P Ditmer; Elizabeth Sinclair; Jeffrey N Martin; Steven G Deeks; Peter Hunt; Edward S Mocarski; Caroline Shiboski
Journal:  PLoS One       Date:  2009-04-17       Impact factor: 3.240

10.  Temporal response of the human virome to immunosuppression and antiviral therapy.

Authors:  Iwijn De Vlaminck; Kiran K Khush; Calvin Strehl; Bitika Kohli; Helen Luikart; Norma F Neff; Jennifer Okamoto; Thomas M Snyder; David N Cornfield; Mark R Nicolls; David Weill; Daniel Bernstein; Hannah A Valantine; Stephen R Quake
Journal:  Cell       Date:  2013-11-21       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.